GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Remedent Inc (OTCPK:REMI) » Definitions » Net Income

Remedent (Remedent) Net Income : $-0.26 Mil (TTM As of Dec. 2020)


View and export this data going back to 2000. Start your Free Trial

What is Remedent Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Remedent's Net Income for the three months ended in Dec. 2020 was $0.09 Mil. Its Net Income for the trailing twelve months (TTM) ended in Dec. 2020 was $-0.26 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Remedent's Earnings per Share (Diluted) for the three months ended in Dec. 2020 was $0.00.


Remedent Net Income Historical Data

The historical data trend for Remedent's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Remedent Net Income Chart

Remedent Annual Data
Trend Mar11 Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.16 0.84 -0.06 2.13 -0.86

Remedent Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.15 -0.36 - - 0.09

Remedent Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Remedent's Net Income for the fiscal year that ended in Mar. 2020 is calculated as

Net Income(A: Mar. 2020 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-0.852+-0.002+0+-0.004
=-0.86

Remedent's Net Income for the quarter that ended in Dec. 2020 is calculated as

Net Income(Q: Dec. 2020 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=0.101+-0.002+0+-0.005
=0.09

Net Income for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Remedent  (OTCPK:REMI) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Remedent's Earnings per Share (Diluted) (EPS) for the quarter that ended in Dec. 2020 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Remedent Net Income Related Terms

Thank you for viewing the detailed overview of Remedent's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Remedent (Remedent) Business Description

Traded in Other Exchanges
N/A
Address
Zuiderlaan 1-3, Box 8, Ghent, BEL, 9000
Remedent Inc is a manufacturer of cosmetic dentistry products in Europe. The company is engaged in the research, development, and manufacturing of oral care and cosmetic dentistry products. It designs, develops, manufactures, and distributes cosmetic dentistry products, including a full line of professional dental products that are distributed in Europe, Asia, the Middle East, and the United States. The product line of the company includes SmileWise, the SmileMe mirror, and the Condor intra-oral 3D scanner.
Executives
Stuart Steinberg 10 percent owner 85 BELLEVUE AVENUE, RYE NY 10580
Marxe Austin W & Greenhouse David M 10 percent owner C/O SPECIAL SITUATIONS FUNDS, 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Gruber & Mcbaine Capital Management Llc 10 percent owner 234 VAN NESS, STE 5, SAN FRANCISCO CA 94133
Stephen Farley Ross director, officer: CFO; Secretary XAVIER DE COCKLAAN 42 DEURLE C9 9831
Fred Kolsteeg director XAVIER DE COCKLAAN 42 DEURLE C9 9831
Acker Philippe Van director C/O REMEDENT, INC. XAVIER DE COCKLAAN 42 9831 DEURLE C9 9831
Robin List other: Former Officer and Director XAVIER DE COCKLAAN 42 DEURLE C9 9831
Roger Leddington officer: Sr VP & Head of US Marketing C/O REMEDENT, INC. XAVIER DE COCKLAAN 42 DEURLE C9 9831
Guy Devreese director, officer: Chairman of the Board XAVIER DE COCKLAAN 42 DEURLE C9 9831
Judd Darrin Hoffman officer: VP Worldwide Sales/Operations 702A JUANITA AVENUE REDONDO BEACH CA 90277
Nv Lausha 10 percent owner C/O REMEDENT, INC. XAVIER DE COCKLAAN 42 9831 DEURLE C9 9831

Remedent (Remedent) Headlines

From GuruFocus

Making Money from Smiles

By Frank Lind Frank Lind 05-26-2011